Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia

British Journal of Haematology

Volumn 160, Issue 5, 2013, Pages 640-648

  Richardson, Simon E ^a   Khan, Iftekhar ^b   Rawstron, Andrew ^c   Sudak, Jagoda ^a   Edwards, Noha ^a   Verfuerth, Stephanie ^a   Fielding, Adele K ^a   Goldstone, Anthony ^d   Kottaridis, Panagiotis ^a   Morris, Emma ^d   Benjamin, Reuben ^d   Peggs, Karl S ^d   Thomson, Kirsty J ^d   Vandenberghe, Elisabeth ^e   Mackinnon, Stephen ^a   Chakraverty, Ronjon ^a  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c St James's Institute of Oncology   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^e ST JAMES S HOSPITAL   (Ireland)

Author keywords

Alemtuzumab; Allogeneic stem cell transplantation; Chronic lymphocytic leukaemia; Donor lymphocyte infusion; T cell depletion

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; FLUDARABINE; MELPHALAN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; B LYMPHOCYTE; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; FEMALE; FOLLOW UP; GRANULOCYTE; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MALE; MINIMAL RESIDUAL DISEASE; MONOCYTE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RELAPSE; REMISSION; RISK REDUCTION; T LYMPHOCYTE; TREATMENT FAILURE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY, ADOPTIVE; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTE REDUCTION PROCEDURES; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM, RESIDUAL; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SALVAGE THERAPY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84873999328     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12197     Document Type: Article

References (20)

1. Atkinson, K., Horowitz, M.M., Gale, R.P., Lee, M.B., Rimm, A.A. & Bortin, M.M. (1989) Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplantation, 4, 247-254.
2. Chakraverty, R., Orti, G., Roughton, M., Shen, J., Fielding, A., Kottaridis, P., Milligan, D., Collin, M., Crawley, C., Johnson, P., Clark, A., Parker, A., Bloor, A., Pettengell, R., Snowden, J., Pettitt, A., Clark, R., Hale, G., Peggs, K., Thomson, K., Morris, E. & Mackinnon, S. (2010) Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood, 116, 3080-3088.
3. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. & Rai, K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990-4997.
4. Delgado, J., Pillai, S., Benjamin, R., Caballero, D., Martino, R., Nathwani, A., Lovell, R., Thomson, K., Perez-Simon, J.A., Sureda, A., Kottaridis, P., Vazquez, L., Peggs, K., Sierra, J., Milligan, D. & Mackinnon, S. (2008) The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Biol Blood Marrow Transplantation, 14, 1288-1297.
5. Dreger, P. (2009) Allotransplantation for chronic lymphocytic leukemia. Hematology American Society of Hematology Education Program, 60, 2-609.
6. Dreger, P., Dohner, H., Ritgen, M., Bottcher, S., Busch, R., Dietrich, S., Bunjes, D., Cohen, S., Schubert, J., Hegenbart, U., Beelen, D., Zeis, M., Stadler, M., Hasenkamp, J., Uharek, L., Scheid, C., Humpe, A., Zenz, T., Winkler, D., Hallek, M., Kneba, M., Schmitz, N. & Stilgenbauer, S. (2010) Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood, 116, 2438-2447.
7. Hallek, M., Cheson, B.D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H., Hillmen, P., Keating, M.J., Montserrat, E., Rai, K.R. & Kipps, T.J. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111, 5446-5456.
8. Lambert, J.R., Bomanji, J.B., Peggs, K.S., Thomson, K.J., Chakraverty, R.K., Fielding, A.K., Kottaridis, P.D., Roughton, M., Morris, E.C., Goldstone, A.H., Linch, D.C., Ell, P.J. & Mackinnon, S. (2010) Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. Blood, 115, 2763-2768.
9. Peggs, K.S., Thomson, K., Hart, D.P., Geary, J., Morris, E.C., Yong, K., Goldstone, A.H., Linch, D.C. & Mackinnon, S. (2004) Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood, 103, 1548-1556.
10. Peggs, K.S., Kayani, I., Edwards, N., Kottaridis, P., Goldstone, A.H., Linch, D.C., Hough, R., Morris, E.C., Fielding, A., Chakraverty, R., Thomson, K.J. & Mackinnon, S. (2011) Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 29, 971-978.
11. Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.G., Beatty, P., Hows, J. & Thomas, E.D. (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplantation, 15, 825-828.
12. Rawstron, A.C., Villamor, N., Ritgen, M., Bottcher, S., Ghia, P., Zehnder, J.L., Lozanski, G., Colomer, D., Moreno, C., Geuna, M., Evans, P.A., Natkunam, Y., Coutre, S.E., Avery, E.D., Rassenti, L.Z., Kipps, T.J., Caligaris-Cappio, F., Kneba, M., Byrd, J.C., Hallek, M.J., Montserrat, E. & Hillmen, P. (2007) International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 21, 956-964.
13. Ritgen, M., Stilgenbauer, S., von Neuhoff, N., Humpe, A., Bruggemann, M., Pott, C., Raff, T., Krober, A., Bunjes, D., Schlenk, R., Schmitz, N., Dohner, H., Kneba, M. & Dreger, P. (2004) Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood, 104, 2600-2602.
14. Ritgen, M., Bottcher, S., Stilgenbauer, S., Bunjes, D., Schubert, J., Cohen, S., Humpe, A., Hallek, M., Kneba, M., Schmitz, N., Dohner, H. & Dreger, P. (2008) Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 22, 1377-1386.
15. Schetelig, J., Thiede, C., Bornhauser, M., Schwerdtfeger, R., Kiehl, M., Beyer, J., Sayer, H.G., Kroger, N., Hensel, M., Scheffold, C., Held, T.K., Hoffken, K., Ho, A.D., Kienast, J., Neubauer, A., Zander, A.R., Fauser, A.A., Ehninger, G. & Siegert, W. (2003) Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 21, 2747-2753.
16. Schetelig, J., van Biezen, A., Brand, R., Caballero, D., Martino, R., Itala, M., Garcia-Marco, J.A., Volin, L., Schmitz, N., Schwerdtfeger, R., Ganser, A., Onida, F., Mohr, B., Stilgenbauer, S., Bornhauser, M., de Witte, T. & Dreger, P. (2008) Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 26, 5094-5100.
17. Sorror, M.L., Storer, B.E., Sandmaier, B.M., Maris, M., Shizuru, J., Maziarz, R., Agura, E., Chauncey, T.R., Pulsipher, M.A., McSweeney, P.A., Wade, J.C., Bruno, B., Langston, A., Radich, J., Niederwieser, D., Blume, K.G., Storb, R. & Maloney, D.G. (2008) Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 26, 4912-4920.
18. Thomson, K.J., Morris, E.C., Milligan, D., Parker, A.N., Hunter, A.E., Cook, G., Bloor, A.J., Clark, F., Kazmi, M., Linch, D.C., Chakraverty, R., Peggs, K.S. & Mackinnon, S. (2010) T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28, 3695-3700.
19. Vago, L., Perna, S.K., Zanussi, M., Mazzi, B., Barlassina, C., Stanghellini, M.T., Perrelli, N.F., Cosentino, C., Torri, F., Angius, A., Forno, B., Casucci, M., Bernardi, M., Peccatori, J., Corti, C., Bondanza, A., Ferrari, M., Rossini, S., Roncarolo, M.G., Bordignon, C., Bonini, C., Ciceri, F. & Fleischhauer, K. (2009) Loss of mismatched HLA in leukemia after stem-cell transplantation. The New England Journal of Medicine, 361, 478-488.
20. Zenz, T., Gribben, J.G., Hallek, M., Dohner, H., Keating, M.J. & Stilgenbauer, S. (2012) Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood, 119, 4101-4107.